NCT07741773Not yet recruiting
Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity
Dietary Supplementation With EVOO Phenolics Prevents MCI Progression to Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The goal of this clinical trial is to determine whether the extra-virgin olive oil (EVOO) phenolic dietary supplement can improve memory function and modulate biomarkers among individuals with mild cognitive impairment (MCI). The main questions it aims to answer are: * Does dietary supplementation with EVOO phenolics improve cognitive function? * What would be the effect of the EVOO dietary supplement on other MCI-related biomarkers, including vascular function and biological pathways? Researchers will compare the EVOO dietary supplements with a placebo (a look-alike substance that contains no EVOO phenolics) Participants will: * Take EVOO dietary supplements or a placebo daily for 6 months * Visit the study site during the 6-month study for screening and testing.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Jul 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Augusta University
- Diseases
- Alzheimer disease
- NCT number
- NCT07741773
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Dec 2026 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History or presence of vascular disease that may affect cognitive function
- History or presence of stroke within the past 1 year
- History of severe, clinically significant CNS trauma
- History of intracranial tumor
- Allergic to the MRI contrast agent "Multihance"
Lab values
- History or presence of kidney disease (eGFR \<60 mL/min/1.73m2)
Other
- Recent transient ischemic attack (TIA) within the past 180 days
- Presence of a pacemaker
- Presence of metal in the body
- Pregnancy
Who the study is looking for
- CDR (Clinical Dementia Rating) score of 0.5 OR MoCA (Montreal Cognitive Assessment) score of 18-25.
Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Georgia prevention institute Coordinator of this site? Confirm its status | Augusta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.